Models for Epilepsy and Epileptogenesis: Report from the NIH Workshop, Bethesda, Maryland

Purpose: The workshop explored the current problems, needs, and potential usefulness of existing methods of discovery of new therapies to treat epilepsy patients. Resistance to medical therapy (pharmacoresistance) and the development of epilepsy (epileptogenesis) are recognized as two of the major p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Epilepsia (Copenhagen) 2002-11, Vol.43 (11), p.1410-1420
Hauptverfasser: Stables, James P., Bertram, Edward H., White, H. Steve, Coulter, Douglas A., Dichter, Marc A., Jacobs, Margaret P., Loscher, Wolfgang, Lowenstein, Daniel H., Moshe, Solomon L., Noebels, Jeffrey L., Davis, Mirian
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1420
container_issue 11
container_start_page 1410
container_title Epilepsia (Copenhagen)
container_volume 43
creator Stables, James P.
Bertram, Edward H.
White, H. Steve
Coulter, Douglas A.
Dichter, Marc A.
Jacobs, Margaret P.
Loscher, Wolfgang
Lowenstein, Daniel H.
Moshe, Solomon L.
Noebels, Jeffrey L.
Davis, Mirian
description Purpose: The workshop explored the current problems, needs, and potential usefulness of existing methods of discovery of new therapies to treat epilepsy patients. Resistance to medical therapy (pharmacoresistance) and the development of epilepsy (epileptogenesis) are recognized as two of the major problems in epilepsy treatment today. At the same time, there is growing awareness that the development of new therapies has slowed, a trend that has economic and scientific roots. To move toward new and more effective therapies, novel approaches to therapy discovery are needed. Methods: A workshop was held in March 2001 with the charge to develop a plan to move the exploration and discovery process forward. Participants from academia, government, and industry reviewed the current status of epilepsy therapy and explored the identification of potential new therapies. Results: At the end of the 2‐day meeting, the panel made a series of recommendations. The two major recommendations were (a) to establish a means for continuing the examination of new approaches to therapy discovery, and (b) to identify models and approaches to therapy discovery that may identify treatments that are more successful than those available. Further recommendations were made to support the development of technology (miniaturization, computerization, video monitoring, etc.) to facilitate the use of the new models and to identify the mechanisms of therapy success and failure. Conclusions: Understanding the epidemiology of therapy resistance and providing support for new approaches to therapy development were identified as key issues for introduction of new and more effective treatments.
doi_str_mv 10.1046/j.1528-1157.2002.06702.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72675779</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72675779</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3612-dab2f9e42a30d34bdc74214622032ba9b4930c9356b8c3e3370e56c09e18446a3</originalsourceid><addsrcrecordid>eNqNkElPwzAQhS0EomX5C8gnTqSMl9gJEgeoClQqixAIcbKyTKAlxcFuRfvvcWgkrlzGM_Z7z6OPEMpgwECq09mAxTyJGIv1gAPwASgd6mqL9LsHpbdJH4CJKI0T6JE972cAoJUWu6THuORCpKJPXm9tibWnlXV01ExrbPyaZp9lNyzsG36in_oz-oiNdQtaOTuni3ekd-Mb-mLdh3-3zQm9xHDny-yE3mZuXYeEA7JTZbXHw-7cJ89Xo6fhTTS5vx4PLyZRIRTjUZnlvEpR8kxAKWReFlpyJhXnIHiepblMBRSpiFWeFAKF0ICxKiBFlkipMrFPjje5jbNfS_QLM5_6AuuwA9qlN5orHWudBmGyERbOeu-wMo2bzsO2hoFpsZqZaemZFqtpsZpfrGYVrEfdH8t8juWfseMYBOcbwXegtv53sBk9jNtO_AAqF4Tn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72675779</pqid></control><display><type>article</type><title>Models for Epilepsy and Epileptogenesis: Report from the NIH Workshop, Bethesda, Maryland</title><source>Wiley Free Content</source><source>MEDLINE</source><source>IngentaConnect Free/Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Stables, James P. ; Bertram, Edward H. ; White, H. Steve ; Coulter, Douglas A. ; Dichter, Marc A. ; Jacobs, Margaret P. ; Loscher, Wolfgang ; Lowenstein, Daniel H. ; Moshe, Solomon L. ; Noebels, Jeffrey L. ; Davis, Mirian</creator><creatorcontrib>Stables, James P. ; Bertram, Edward H. ; White, H. Steve ; Coulter, Douglas A. ; Dichter, Marc A. ; Jacobs, Margaret P. ; Loscher, Wolfgang ; Lowenstein, Daniel H. ; Moshe, Solomon L. ; Noebels, Jeffrey L. ; Davis, Mirian</creatorcontrib><description>Purpose: The workshop explored the current problems, needs, and potential usefulness of existing methods of discovery of new therapies to treat epilepsy patients. Resistance to medical therapy (pharmacoresistance) and the development of epilepsy (epileptogenesis) are recognized as two of the major problems in epilepsy treatment today. At the same time, there is growing awareness that the development of new therapies has slowed, a trend that has economic and scientific roots. To move toward new and more effective therapies, novel approaches to therapy discovery are needed. Methods: A workshop was held in March 2001 with the charge to develop a plan to move the exploration and discovery process forward. Participants from academia, government, and industry reviewed the current status of epilepsy therapy and explored the identification of potential new therapies. Results: At the end of the 2‐day meeting, the panel made a series of recommendations. The two major recommendations were (a) to establish a means for continuing the examination of new approaches to therapy discovery, and (b) to identify models and approaches to therapy discovery that may identify treatments that are more successful than those available. Further recommendations were made to support the development of technology (miniaturization, computerization, video monitoring, etc.) to facilitate the use of the new models and to identify the mechanisms of therapy success and failure. Conclusions: Understanding the epidemiology of therapy resistance and providing support for new approaches to therapy development were identified as key issues for introduction of new and more effective treatments.</description><identifier>ISSN: 0013-9580</identifier><identifier>EISSN: 1528-1167</identifier><identifier>DOI: 10.1046/j.1528-1157.2002.06702.x</identifier><identifier>PMID: 12423393</identifier><language>eng</language><publisher>Boston, MA, USA: Blackwell Science Inc</publisher><subject>Animals ; Anticonvulsants - therapeutic use ; Antiepileptogenesis ; Child, Preschool ; Disease Models, Animal ; Drug Resistance ; Epilepsy ; Epilepsy - drug therapy ; Epilepsy - etiology ; Humans ; Pediatric epilepsy ; Resistant epilepsy ; Technology, Pharmaceutical - methods</subject><ispartof>Epilepsia (Copenhagen), 2002-11, Vol.43 (11), p.1410-1420</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3612-dab2f9e42a30d34bdc74214622032ba9b4930c9356b8c3e3370e56c09e18446a3</citedby><cites>FETCH-LOGICAL-c3612-dab2f9e42a30d34bdc74214622032ba9b4930c9356b8c3e3370e56c09e18446a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1528-1157.2002.06702.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1528-1157.2002.06702.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12423393$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stables, James P.</creatorcontrib><creatorcontrib>Bertram, Edward H.</creatorcontrib><creatorcontrib>White, H. Steve</creatorcontrib><creatorcontrib>Coulter, Douglas A.</creatorcontrib><creatorcontrib>Dichter, Marc A.</creatorcontrib><creatorcontrib>Jacobs, Margaret P.</creatorcontrib><creatorcontrib>Loscher, Wolfgang</creatorcontrib><creatorcontrib>Lowenstein, Daniel H.</creatorcontrib><creatorcontrib>Moshe, Solomon L.</creatorcontrib><creatorcontrib>Noebels, Jeffrey L.</creatorcontrib><creatorcontrib>Davis, Mirian</creatorcontrib><title>Models for Epilepsy and Epileptogenesis: Report from the NIH Workshop, Bethesda, Maryland</title><title>Epilepsia (Copenhagen)</title><addtitle>Epilepsia</addtitle><description>Purpose: The workshop explored the current problems, needs, and potential usefulness of existing methods of discovery of new therapies to treat epilepsy patients. Resistance to medical therapy (pharmacoresistance) and the development of epilepsy (epileptogenesis) are recognized as two of the major problems in epilepsy treatment today. At the same time, there is growing awareness that the development of new therapies has slowed, a trend that has economic and scientific roots. To move toward new and more effective therapies, novel approaches to therapy discovery are needed. Methods: A workshop was held in March 2001 with the charge to develop a plan to move the exploration and discovery process forward. Participants from academia, government, and industry reviewed the current status of epilepsy therapy and explored the identification of potential new therapies. Results: At the end of the 2‐day meeting, the panel made a series of recommendations. The two major recommendations were (a) to establish a means for continuing the examination of new approaches to therapy discovery, and (b) to identify models and approaches to therapy discovery that may identify treatments that are more successful than those available. Further recommendations were made to support the development of technology (miniaturization, computerization, video monitoring, etc.) to facilitate the use of the new models and to identify the mechanisms of therapy success and failure. Conclusions: Understanding the epidemiology of therapy resistance and providing support for new approaches to therapy development were identified as key issues for introduction of new and more effective treatments.</description><subject>Animals</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Antiepileptogenesis</subject><subject>Child, Preschool</subject><subject>Disease Models, Animal</subject><subject>Drug Resistance</subject><subject>Epilepsy</subject><subject>Epilepsy - drug therapy</subject><subject>Epilepsy - etiology</subject><subject>Humans</subject><subject>Pediatric epilepsy</subject><subject>Resistant epilepsy</subject><subject>Technology, Pharmaceutical - methods</subject><issn>0013-9580</issn><issn>1528-1167</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkElPwzAQhS0EomX5C8gnTqSMl9gJEgeoClQqixAIcbKyTKAlxcFuRfvvcWgkrlzGM_Z7z6OPEMpgwECq09mAxTyJGIv1gAPwASgd6mqL9LsHpbdJH4CJKI0T6JE972cAoJUWu6THuORCpKJPXm9tibWnlXV01ExrbPyaZp9lNyzsG36in_oz-oiNdQtaOTuni3ekd-Mb-mLdh3-3zQm9xHDny-yE3mZuXYeEA7JTZbXHw-7cJ89Xo6fhTTS5vx4PLyZRIRTjUZnlvEpR8kxAKWReFlpyJhXnIHiepblMBRSpiFWeFAKF0ICxKiBFlkipMrFPjje5jbNfS_QLM5_6AuuwA9qlN5orHWudBmGyERbOeu-wMo2bzsO2hoFpsZqZaemZFqtpsZpfrGYVrEfdH8t8juWfseMYBOcbwXegtv53sBk9jNtO_AAqF4Tn</recordid><startdate>200211</startdate><enddate>200211</enddate><creator>Stables, James P.</creator><creator>Bertram, Edward H.</creator><creator>White, H. Steve</creator><creator>Coulter, Douglas A.</creator><creator>Dichter, Marc A.</creator><creator>Jacobs, Margaret P.</creator><creator>Loscher, Wolfgang</creator><creator>Lowenstein, Daniel H.</creator><creator>Moshe, Solomon L.</creator><creator>Noebels, Jeffrey L.</creator><creator>Davis, Mirian</creator><general>Blackwell Science Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200211</creationdate><title>Models for Epilepsy and Epileptogenesis: Report from the NIH Workshop, Bethesda, Maryland</title><author>Stables, James P. ; Bertram, Edward H. ; White, H. Steve ; Coulter, Douglas A. ; Dichter, Marc A. ; Jacobs, Margaret P. ; Loscher, Wolfgang ; Lowenstein, Daniel H. ; Moshe, Solomon L. ; Noebels, Jeffrey L. ; Davis, Mirian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3612-dab2f9e42a30d34bdc74214622032ba9b4930c9356b8c3e3370e56c09e18446a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Animals</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Antiepileptogenesis</topic><topic>Child, Preschool</topic><topic>Disease Models, Animal</topic><topic>Drug Resistance</topic><topic>Epilepsy</topic><topic>Epilepsy - drug therapy</topic><topic>Epilepsy - etiology</topic><topic>Humans</topic><topic>Pediatric epilepsy</topic><topic>Resistant epilepsy</topic><topic>Technology, Pharmaceutical - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stables, James P.</creatorcontrib><creatorcontrib>Bertram, Edward H.</creatorcontrib><creatorcontrib>White, H. Steve</creatorcontrib><creatorcontrib>Coulter, Douglas A.</creatorcontrib><creatorcontrib>Dichter, Marc A.</creatorcontrib><creatorcontrib>Jacobs, Margaret P.</creatorcontrib><creatorcontrib>Loscher, Wolfgang</creatorcontrib><creatorcontrib>Lowenstein, Daniel H.</creatorcontrib><creatorcontrib>Moshe, Solomon L.</creatorcontrib><creatorcontrib>Noebels, Jeffrey L.</creatorcontrib><creatorcontrib>Davis, Mirian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Epilepsia (Copenhagen)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stables, James P.</au><au>Bertram, Edward H.</au><au>White, H. Steve</au><au>Coulter, Douglas A.</au><au>Dichter, Marc A.</au><au>Jacobs, Margaret P.</au><au>Loscher, Wolfgang</au><au>Lowenstein, Daniel H.</au><au>Moshe, Solomon L.</au><au>Noebels, Jeffrey L.</au><au>Davis, Mirian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Models for Epilepsy and Epileptogenesis: Report from the NIH Workshop, Bethesda, Maryland</atitle><jtitle>Epilepsia (Copenhagen)</jtitle><addtitle>Epilepsia</addtitle><date>2002-11</date><risdate>2002</risdate><volume>43</volume><issue>11</issue><spage>1410</spage><epage>1420</epage><pages>1410-1420</pages><issn>0013-9580</issn><eissn>1528-1167</eissn><abstract>Purpose: The workshop explored the current problems, needs, and potential usefulness of existing methods of discovery of new therapies to treat epilepsy patients. Resistance to medical therapy (pharmacoresistance) and the development of epilepsy (epileptogenesis) are recognized as two of the major problems in epilepsy treatment today. At the same time, there is growing awareness that the development of new therapies has slowed, a trend that has economic and scientific roots. To move toward new and more effective therapies, novel approaches to therapy discovery are needed. Methods: A workshop was held in March 2001 with the charge to develop a plan to move the exploration and discovery process forward. Participants from academia, government, and industry reviewed the current status of epilepsy therapy and explored the identification of potential new therapies. Results: At the end of the 2‐day meeting, the panel made a series of recommendations. The two major recommendations were (a) to establish a means for continuing the examination of new approaches to therapy discovery, and (b) to identify models and approaches to therapy discovery that may identify treatments that are more successful than those available. Further recommendations were made to support the development of technology (miniaturization, computerization, video monitoring, etc.) to facilitate the use of the new models and to identify the mechanisms of therapy success and failure. Conclusions: Understanding the epidemiology of therapy resistance and providing support for new approaches to therapy development were identified as key issues for introduction of new and more effective treatments.</abstract><cop>Boston, MA, USA</cop><pub>Blackwell Science Inc</pub><pmid>12423393</pmid><doi>10.1046/j.1528-1157.2002.06702.x</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0013-9580
ispartof Epilepsia (Copenhagen), 2002-11, Vol.43 (11), p.1410-1420
issn 0013-9580
1528-1167
language eng
recordid cdi_proquest_miscellaneous_72675779
source Wiley Free Content; MEDLINE; IngentaConnect Free/Open Access Journals; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Animals
Anticonvulsants - therapeutic use
Antiepileptogenesis
Child, Preschool
Disease Models, Animal
Drug Resistance
Epilepsy
Epilepsy - drug therapy
Epilepsy - etiology
Humans
Pediatric epilepsy
Resistant epilepsy
Technology, Pharmaceutical - methods
title Models for Epilepsy and Epileptogenesis: Report from the NIH Workshop, Bethesda, Maryland
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T03%3A33%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Models%20for%20Epilepsy%20and%20Epileptogenesis:%20Report%20from%20the%20NIH%20Workshop,%20Bethesda,%20Maryland&rft.jtitle=Epilepsia%20(Copenhagen)&rft.au=Stables,%20James%E2%80%83P.&rft.date=2002-11&rft.volume=43&rft.issue=11&rft.spage=1410&rft.epage=1420&rft.pages=1410-1420&rft.issn=0013-9580&rft.eissn=1528-1167&rft_id=info:doi/10.1046/j.1528-1157.2002.06702.x&rft_dat=%3Cproquest_cross%3E72675779%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72675779&rft_id=info:pmid/12423393&rfr_iscdi=true